Blood lipids, blood glucose, blood homocysteine, routine blood, blood coagulation, and liver and kidney function should be monitored for cerebral infarction. The main risk factors for cerebral infarction include hyperlipidemia, hyperglycemia, and hyperhomocysteinemia. Patients with hyperlipidemia should be treated with statins to regulate lipids and stabilize plaque, and liver function should be monitored during medication. Statins should be disabled if transaminases are elevated more than three times the normal value. If patients have elevated blood glucose, they can be treated with oral metformin or subcutaneous insulin injections. Those with elevated homocysteine can be treated with oral vitamin B6, folic acid tablets, adenosylcobalamin and or methylcobalamin. If the patient is antiplatelet aggregating, blood work should be monitored and blood pressure must be monitored in patients on anticoagulation therapy. Patients should have their renal function monitored if they are on butalbital and edaravone. Both of these drugs should be used with caution or contraindicated in patients with poor renal function.